期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多黏菌素类药物疗效和安全性研究进展

Study advances for efficacy and safety of polymyxins
原文传递
导出
摘要 多黏菌素E和多黏菌素B是从多黏芽孢杆菌培养液中获得的多肽类抗生素，临床用于治疗铜绿假单胞菌，鲍曼不动杆菌和肺炎克雷伯菌等耐药菌感染。多黏菌素E的不良反应为肾毒性和神经系统毒性。其中年龄、给药剂量和联用其他药物是发生肾毒性的风险因素。与抗氧化剂、自由基清除剂和某些对肾脏有保护作用的中药联用，可能降低多黏菌素E的肾毒性并提高疗效。肾功能不全者应用多黏菌素E和多黏菌素B无需调整给药剂量。多黏菌素的新型衍生物肾毒性较低。 Polymyxin E and polymyxin B were the polypeptide antibiotic which were obtained from the Bacillus polymyxa medium. They were used to treat the resistant bacterial infection with Pseudomonas aeruginosa,Acinetobacter baumannii and Klebsiella pneumonia. The adverse reactions of polymyxin E were renal toxicity and nervous system toxicity. Age,dose and the combination with other drugs are the risk factors of renal toxicity. Combination with antioxidant,free radical scavenger and some Chinese medicine with protective effect on the kidney may reduce the renal toxicity of polymyxin E and improve the curative effect. Patients with renal insufficiency do not need to adjust the dose when they used polymyxin E and polymyxin B. Novel derivatives of polymyxin had lower renal toxicity.
作者 高儒雅 朱孔彩 胡欣 曹国颖
机构地区 北京医院药学部 北京大学医学部药事管理与临床药学系
出处 《药物不良反应杂志》 CSCD 2014年第5期297-299,共3页 Adverse Drug Reactions Journal
关键词 多黏菌素类 治疗效果 安全 Polymyxins Treatment outcome Safety
分类号 R978.1 [医药卫生—药品]
  • 相关文献

参考文献22

  • 1赵苗,张菁,张婴元.多黏菌素临床药理学研究新进展[J].中国感染与化疗杂志,2012,12(6):466-471. 被引量：4
  • 2Couet W, Gr6goire N, Gobin P, et al. Pharmacokinetics ot cohs- tin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers [ J ]. Clin Pharmaeol Ther, 2011, 89(6): 875-879.
  • 3Marchand S, Frat JP, Petitpas F, et al. Removal of colistin during intermittent haemodialysis in two critically ill patients[ J]. J Anti- microb Chemother, 2010, 65 (8) : 1836-1837.
  • 4Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fi- brosis[ J]. J Antimicrob Chemother, 2003, 52 (6) : 987-992.
  • 5Plachouras D, Karvanen M, Friberg LE, et al. Population phar- macokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria [ J ]. Antimicrob Agents Che- mother, 2009, 53 (8) :3430-3436.
  • 6Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill[ J]. Antimicrob Agents Chemother, 2012 , 56 (8) : 4241-4249.
  • 7Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-in- terval calistin administration in critically ill patients: is this the right dosing strategy? A preliminary study [ J ]. Clin Infect Dis, 2012, 54(12) : 1720-1726.
  • 8Antachopoulos C, Karvanen M, Iosifidis E, et al. Serum and ce-rebrospinal fluid levels of colistin in pediatric patients[J]. Antimi- crob Agents Chemother, 2010, 54(9) : 3985-3987.
  • 9Tamma PD, Newland JG, Pannaraj PS, et al. The use of intrave- nous colistin among children in the United States: results from a multicenter, ease series[J]. Pediatr Infect Dis J, 2013, 32(1 ) : 17-22.
  • 10Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin phannacotherapy [J]. Pharmacotherapy, 2013, 33 (8) :812-816.

二级参考文献33

  • 1Falagas ME, Kasiakou SK. Colistin, the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial in?fections[J]. Clin Infect Dis, 2005,40 (9) , 1333-1341.
  • 2Landman D, Georgescu C, Martin DA, et al. Polymyxins revisi?ted[J]. Clin Microbiol Rev, 2008,21(3) ,449-465.
  • 3Li J, Nation RL, Turnidge JD, et al. Colistin, the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infec?tions[J]. Lancet Infect Dis, 2006,6(9) ,589-601.
  • 4Owen RJ, Li J, Nation RL, et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates[J]. J An?timicrob Chemother, 2007,59(3) ,473-477.
  • 5Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens, results from the SENTRY Antimicrobial Surveillance Program (2006-09)[J]. J Antimicrob Chemother , 2011,66(9), 2070-2074.
  • 6Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii [J]. Antimicrob A?gents Chernother , 2006,50(9) ,2946-2950.
  • 7Gupta S, Govil D, Kakar PN, et al. Colistin and polymyxin B, a re-emergence[J]. Indian J Crit Care Med, 2009,13(2) ,49-53.
  • 8Miller AK, Brannon MK, Stevens L, et al. PhoQ mutations pro?mote lipid A modification and polymyxin resistance of Pseudo?monas aeruginosa found in colistin-treated cystic fibrosis patients [J]. Antimicrob Agents Chemother , 2011,55(12) ,5761-5769.
  • 9Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk fac?tors associated with the isolation of colistin-resistant gram-negative bacteria, a matched case-control study[J]. Crit Care Med , 2008, 36(3) ,807-811.
  • 10Bergen PJ, Li J, Rayner CR, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa [J]. Antimicrob Agents Chernother , 2006,50(6): 1953-1958.

共引文献3

药物不良反应杂志
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部